It is a huge honour to be invited to contribute to a Cochrane Report which has, for the past 20 years been globally recognized as representing the highest standard in evidence-based health care.Dr Richard Wyse – Director of Research, Cure Parkinson’s
“This report, draws attention to the future potential treatment of Parkinson’s disease by GLP-1 agonist drugs, which is a growing and important area of clinical research, and which has been spearheaded in recent years by Cure Parkinson’s who have launched trials of Exenatide, Liraglutide and Lixisenatide in various groups of Parkinsons patients, with some trials already completed. Since the report was commissioned, we have seen further growth in this important area of research with the start of the Neuraly trials (NY001) and the Korean company, Peptron, also starting clinical trials.”
We are sorry that this content was not useful for you
Let us improve this content
Can you tell us how we can improve this content?